Januvia no longer contraindicated in renal impairment

Januvia (sitagliptin) can now be used at a lower dose in patients with moderate to severe renal impairment.

No dose adjustment is required based on age
No dose adjustment is required based on age

Clinical study

In an open-label study, the pharmacokinetics of Januvia (sitagliptin) were assessed in patients with differing degrees of renal impairment and those with end-stage renal disease on haemodialysis (ESRD). Patients were administered a reduced single dose of 50mg sitagliptin.

A clinically significant increase in plasma concentration of sitagliptin was not observed in patients with mild renal impairment in comparison with normal healthy patients. In contrast, an approximate 2-fold increase in plasma AUC of sitagliptin was seen in patients with moderate renal impairment and an approximate 4-fold increase was observed in patients with severe renal impairment and patients with ESRD on haemodialysis.

Dosage recommendations

No dose adjustment is required in patients with mild renal insufficiency (CrCl ≥50ml/min). For patients with moderate renal impairment (CrCl 30 to 50ml/min), the dose of Januvia is 50mg once daily. In patients with severe renal impairment (CrCl <30ml/min) or end-stage renal disease requiring dialysis, the dose of Januvia is 25mg once daily.

Renal function should be assessed before starting and measured periodically thereafter.

Recommendations do not apply to Janumet

The combination product Janumet (sitagliptin + metformin) is still contraindicated in patients with moderate to severe renal impairment owing to the metformin component.

View Januvia drug record

View Janumet drug record

Further information: Merck Sharp & Dohme Ltd

Updated 27 April 2012

New strengths of Januvia available

Januvia is now available as 25mg and 50mg tablets to facilitate dosing in moderate to severe renal impairment.

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...